| Year |
Citation |
Score |
| 2024 |
Fléchon A, Morales-Barrera R, Powles T, Alva A, Özgüroğlu M, Csöszi T, Loriot Y, Rodriguez-Vida A, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Gunduz S, Mamtani R, ... ... Lunceford J, et al. Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF12. PMID 39475359 DOI: 10.1158/1078-0432.CCR-23-3518 |
0.358 |
|
| 2022 |
Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Bhagia P, ... ... Lunceford J, et al. T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. Future Oncology (London, England). PMID 35852104 DOI: 10.2217/fon-2021-1134 |
0.398 |
|
| 2022 |
Bellmunt J, de Wit R, Fradet Y, Climent MA, Petrylak DP, Lee JL, Fong L, Necchi A, Sternberg CN, O'Donnell PH, Powles T, Plimack ER, Bajorin DF, Balar AV, Castellano D, ... ... Lunceford J, et al. Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35247908 DOI: 10.1158/1078-0432.CCR-21-3089 |
0.38 |
|
| 2020 |
Winer EP, Lipatov O, Im S, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Testa L, Witzel I, Ohtani S, Lunceford J, Karantza V, Mejia JA, Cristescu R, Aurora-Garg D, et al. Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119. Journal of Clinical Oncology. 38: 1013-1013. DOI: 10.1200/Jco.2020.38.15_Suppl.1013 |
0.355 |
|
| 2020 |
Cho BC, Lopes G, Kowalski DM, Kasahara K, Wu Y, Castro G, Turna HZ, Cristescu R, Aurora-Garg D, Loboda A, Lunceford J, Kobie J, Ayers M, Pietanza MC, Piperdi B, et al. Abstract CT084: Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct084 |
0.429 |
|
| 2020 |
Daud A, Carlino MS, Ribas A, Arance A, Grob J, Larkin J, Long GV, Schachter J, Webber AL, Krepler C, Zhang C, Lunceford J, Cristescu R, Zhao Q, Ma J, et al. Abstract 2009: Evaluation of RNA-sequencing signatures with response to pembrolizumab (pembro) monotherapy in ipilimumab-naive patients (pts) with melanoma Clinical Trials. 80: 2009-2009. DOI: 10.1158/1538-7445.Am2020-2009 |
0.376 |
|
| 2019 |
Grivas P, Castellano DE, O'Donnell PH, Cristescu R, Frenkl TL, Keefe SM, Loboda A, Souza SC, Ma H, Snyder A, Zhang C, Albright A, Lunceford J, Balar AV. Association between stromal/TGF-β/EMT gene expression signature and response to pembrolizumab monotherapy in cisplatin-ineligible patients with locally advanced (unresectable) or metastatic urothelial carcinoma. Journal of Clinical Oncology. 37: 433-433. DOI: 10.1200/Jco.2019.37.7_Suppl.433 |
0.448 |
|
| 2019 |
Loi S, Schmid P, Cortés J, Cescon DW, Winer EP, Toppmeyer D, Rugo HS, Laurentiis MD, Nanda R, Iwata H, Awada A, Tan A, Zhang C, Loboda A, Albright A, ... ... Lunceford J, et al. Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086 Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-225 |
0.492 |
|
| 2019 |
Ribas A, Robert C, Schachter J, Long GV, Arance A, Carlino MS, Larkin J, Webber AL, Lunceford J, Zhao Q, Cristescu R, Nebozhyn M, Zhang C, Blumenschein W, Krepler C, et al. Abstract 4217: Tumor mutational burden (TMB), T cell-inflamed gene expression profile (GEP) and PD-L1 are independently associated with response to pembrolizumab (Pembro) in patients with advanced melanoma in the KEYNOTE (KN)-006 study Cancer Research. 79: 4217-4217. DOI: 10.1158/1538-7445.Am2019-4217 |
0.503 |
|
| 2019 |
Herbst RS, Lopes G, Kowalski DM, Kasahara K, Wu Y-, Castro GD, Cho BC, Turna HZ, Cristescu R, Aurora-Garg D, Lunceford J, Kobie J, Ayers M, Pietanza MC, Piperdi B, et al. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042 Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz453.001 |
0.304 |
|
| 2019 |
Herbst RS, Lopes G, Kowalski DM, Nishio M, Wu Y-, Junior GdC, Baas P, Kim D-, Gubens MA, Cristescu R, Aurora-Garg D, Albright A, Ayers M, Loboda A, Lunceford J, et al. Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz394.077 |
0.442 |
|
| 2019 |
Garassino M, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, Speranza G, Reck M, Hui R, Boyer M, Cristescu R, Aurora-Garg D, Albright A, Loboda A, Kobie J, Lunceford J, et al. OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.427 |
0.305 |
|
| 2018 |
Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Kim HT, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, ... ... Lunceford J, et al. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. Jama Oncology. PMID 30570649 DOI: 10.1001/Jamaoncol.2018.5441 |
0.341 |
|
| 2018 |
Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, ... ... Lunceford JK, et al. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018782276. PMID 30557521 DOI: 10.1200/Jco.2018.78.2276 |
0.456 |
|
| 2018 |
Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, Zhang C, Lunceford JK, Joe A, Cheng J, Webber AL, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science (New York, N.Y.). 362. PMID 30309915 DOI: 10.1126/Science.Aar3593 |
0.498 |
|
| 2018 |
Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D, Ms MJ, Shah S, Hanks D, Wang J, Lunceford J, Savage MJ, Juco J, Emancipator K. Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer. Archives of Pathology & Laboratory Medicine. PMID 30028179 DOI: 10.5858/Arpa.2018-0043-Oa |
0.393 |
|
| 2018 |
Seiwert TY, Cristescu R, Mogg R, Ayers M, Albright A, Sher X, Liu X, Nebozhyn M, Zhang C, Lunceford J, Joe AK, Cheng JD, Webber AL, Ibrahim N, Plimack ER, et al. Genomic biomarkers in relation to PD-1 checkpoint blockade response. Journal of Clinical Oncology. 36: 25-25. DOI: 10.1200/Jco.2018.36.5_Suppl.25 |
0.454 |
|
| 2018 |
Kulangara K, Guerrero L, Posch A, Boyer S, Hanks DA, Carnahan J, Wang J, Lunceford J, Savage M, Marton MJ, Pruitt SK, Juco JW, Emancipator K. Investigation of PD-L1 expression and response to pembrolizumab (pembro) in gastric cancer (GC) and cervical cancer (CC) using combined positive score (CPS) and tumor proportion score (TPS). Journal of Clinical Oncology. 36: 4065-4065. DOI: 10.1200/Jco.2018.36.15_Suppl.4065 |
0.456 |
|
| 2018 |
Liu X, Lee J, Lee SJ, Cho JH, Sun J, Zhang L, Pei Y, Chen L, Dolled-Filhart M, Emancipator K, Lunceford J, Chen R, Zhou W, Kim J. Abstract 4213: Molecular biomarker study of programmed death receptor ligand 1 (PD-L1) in Korean patients with lung adenocarcinoma Epidemiology. DOI: 10.1158/1538-7445.Am2018-4213 |
0.385 |
|
| 2017 |
Doi T, Piha-Paul SA, Jalal SI, Saraf S, Lunceford J, Koshiji M, Bennouna J. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017749846. PMID 29116900 DOI: 10.1200/Jco.2017.74.9846 |
0.48 |
|
| 2017 |
Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A, McClanahan TK. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. The Journal of Clinical Investigation. PMID 28650338 DOI: 10.1172/Jci91190 |
0.496 |
|
| 2017 |
Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY, Handa M, Tomassini JE, McClanahan T. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 23: 3158-3167. PMID 28619999 DOI: 10.1158/1078-0432.Ccr-16-1761 |
0.465 |
|
| 2017 |
Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQ, Juco J, Lunceford J, Saraf S, Perini RF, O'Donnell PH. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. The Lancet. Oncology. PMID 28081914 DOI: 10.1016/S1470-2045(17)30007-4 |
0.464 |
|
| 2017 |
Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu X, Nebozhyn M, Lunceford JK, Joe AK, Cheng J, Plimack ER, Ott PA, Seiwert TY, et al. Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab. Journal of Clinical Oncology. 35: 1-1. DOI: 10.1200/Jco.2017.35.7_Suppl.1 |
0.474 |
|
| 2017 |
O'Donnell PH, Grivas P, Balar AV, Bellmunt J, Vuky J, Powles T, Plimack ER, Hahn NM, Wit RD, Pang L, Savage MJ, Lunceford JK, Keefe SM, Bajorin DF, Castellano D. Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). Journal of Clinical Oncology. 35: 4502-4502. DOI: 10.1200/Jco.2017.35.15_Suppl.4502 |
0.407 |
|
| 2017 |
Ott PA, Bang Y, Razak ARA, Bennouna J, Soria J, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, Brummelen Ev, Levitan D, Zhao G, Emancipator K, ... ... Lunceford J, et al. 84PDRelationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028) Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx363 |
0.457 |
|
| 2016 |
Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, ... ... Lunceford JK, et al. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 4102-4109. PMID 27863197 DOI: 10.1200/Jco.2016.67.2477 |
0.507 |
|
| 2016 |
Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. The Lancet. Oncology. PMID 27247226 DOI: 10.1016/S1470-2045(16)30066-3 |
0.394 |
|
| 2016 |
Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. The Lancet. Oncology. PMID 27157491 DOI: 10.1016/S1470-2045(16)00175-3 |
0.466 |
|
| 2016 |
Chow LQM, Mehra R, Haddad RI, Mahipal A, Weiss J, Berger R, Eder JP, Burtness B, Tahara M, Keam B, Le DT, Muro K, Geva R, Chung HC, Lin C, ... ... Lunceford JK, et al. Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Journal of Clinical Oncology. 34: 6010-6010. DOI: 10.1200/Jco.2016.34.15_Suppl.6010 |
0.457 |
|
| 2016 |
Wallden B, Pekker I, Popa S, Dowidar N, Sullivan A, Hood T, Danaher P, Mashadi-Hossein A, Lunceford JK, Marton MJ, Chang KCN, Ferree S, Storhoff JJ. Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System. Journal of Clinical Oncology. 34: 3034-3034. DOI: 10.1200/Jco.2016.34.15_Suppl.3034 |
0.447 |
|
| 2016 |
Piha-Paul SA, Bennouna J, Albright A, Nebozhyn M, McClanahan T, Ayers M, Lunceford JK, Ott PA. T-cell inflamed phenotype gene expression signatures to predict clinical benefit from pembrolizumab across multiple tumor types. Journal of Clinical Oncology. 34: 1536-1536. DOI: 10.1200/Jco.2016.34.15_Suppl.1536 |
0.443 |
|
| 2015 |
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, ... ... Lunceford JK, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. The New England Journal of Medicine. 372: 2018-28. PMID 25891174 DOI: 10.1056/Nejmoa1501824 |
0.469 |
|
| 2015 |
Lunceford JK. Clinical utility estimation for assay cutoffs in early phase oncology enrichment trials. Pharmaceutical Statistics. 14: 233-341. PMID 25846276 DOI: 10.1002/Pst.1679 |
0.315 |
|
| 2015 |
Muro K, Bang Y, Shankaran V, Geva R, Catenacci DVT, Gupta S, Eder JP, Berger R, Gonzalez EJ, Ray A, Dolled-Filhart M, Emancipator K, Pathiraja K, Lunceford JK, Cheng JD, et al. Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. Journal of Clinical Oncology. 33: 4001-4001. DOI: 10.1200/Jco.2015.33.3_Suppl.3 |
0.509 |
|
| 2015 |
Seiwert TY, Burtness B, Weiss J, Eder JP, Yearley J, Murphy E, Nebozhyn M, McClanahan T, Ayers M, Lunceford JK, Mehra R, Heath K, Cheng JD, Chow LQ. Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. Journal of Clinical Oncology. 33: 6017-6017. DOI: 10.1200/Jco.2015.33.15_Suppl.6017 |
0.451 |
|
| 2015 |
Plimack ER, Bellmunt J, Gupta S, Berger R, Montgomery RB, Heath K, Juco J, Emancipator K, Pathiraja K, Lunceford JK, Perini RF, O'Donnell PH. Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012. Journal of Clinical Oncology. 33: 4502-4502. DOI: 10.1200/Jco.2015.33.15_Suppl.4502 |
0.435 |
|
| 2015 |
Shankaran V, Muro K, Bang Y, Geva R, Catenacci DVT, Gupta S, Eder JP, Berger R, Loboda A, Albright A, Cristescu R, Murphy E, McClanahan T, Ayers M, Nebozhyn M, ... Lunceford JK, et al. Correlation of gene expression signatures and clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475). Journal of Clinical Oncology. 33: 3026-3026. DOI: 10.1200/Jco.2015.33.15_Suppl.3026 |
0.419 |
|
| 2015 |
Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu W, Weber JS, Zarour HM, Kefford R, Loboda A, Albright A, Kang SP, Ebbinghaus S, Yearley J, Murphy E, ... ... Lunceford JK, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. Journal of Clinical Oncology. 33: 3001-3001. DOI: 10.1200/Jco.2015.33.15_Suppl.3001 |
0.41 |
|
| 2015 |
Hirsch H, Pinheiro E, Ayers M, Lunceford J, Nebozhyn M, Murphy E, Cai M, Ma Y, Sathe M, McClanahan T. Preclinical to clinical translation of anti-PD-1 blockade Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P92 |
0.419 |
|
| 2015 |
Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Albright A, Cheng J, Kang SP, Ebbinghaus S, Yearley J, Shankaran V, Seiwert T, Ribas A, McClanahan T. Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors Journal For Immunotherapy of Cancer. 3: 80. DOI: 10.1186/2051-1426-3-S2-P80 |
0.411 |
|
| 2015 |
Ayers MD, Nebozhyn M, Hirsch HA, Cristescu R, Murphy EE, Kang SP, Ebbinghaus SW, McClanahan TK, Loboda A, Lunceford JK. Abstract 1307: Assessment of gene expression in peripheral blood from patients with advanced melanoma using RNA-seq before and after treatment with anti-PD-1 therapy with pembrolizumab (MK-3475) Cancer Research. 75: 1307-1307. DOI: 10.1158/1538-7445.Am2015-1307 |
0.496 |
|
| 2015 |
Bang Y-, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Berger R, Emancipator K, Pathiraja K, McClanahan T, Ayers M, Lunceford J, Cheng J, Koshiji M, et al. LBA-04Clinical outcomes and their correlation with gene expression in patients with advanced gastric cancer treated with pembrolizumab (MK-3475): KEYNOTE-012 Annals of Oncology. 26. DOI: 10.1093/Annonc/Mdv262.04 |
0.345 |
|
| 2014 |
Kefford R, Ribas A, Hamid O, Robert C, Daud A, Wolchok JD, Joshua AM, Hodi FS, Gangadhar TC, Hersey P, Weber JS, Dronca RS, Patnaik A, Zarour HM, Dolled-Filhart M, ... Lunceford J, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. Journal of Clinical Oncology. 32: 3005-3005. DOI: 10.1200/Jco.2014.32.15_Suppl.3005 |
0.487 |
|
| 2014 |
Gandhi L, Balmanoukian A, Hui R, Hamid O, Rizvi NA, Leighl N, Gubens M, Goldman JW, Lubiniecki GM, Emancipator K, Dolled-Filhart M, Lunceford JK, Niewood M, Gergich K, Garon EB. Abstract CT105: MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct105 |
0.497 |
|
| 2014 |
Daud AI, Hamid O, Ribas A, Hodi FS, Hwu W, Kefford R, Wolchok J, Hersey P, Weber JS, Joseph R, Gangadhar TC, Dronca RS, Patnaik A, Zarour H, Joshua AM, ... ... Lunceford JK, et al. Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct104 |
0.469 |
|
| 2014 |
Chow L, Burtness B, Weiss J, Berger R, Eder J, Gonzalez E, Pulini J, Johnson J, Dolled-Filhart M, Emancipator K, Lunceford J, Pathiraja K, Gause C, Cheng J, Seiwert T. A Phase Ib Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Human Papiilloma Virus (Hpv)-Positive and Negative Head and Neck Cancer (Hnc) Annals of Oncology. 25: v1. DOI: 10.1093/Annonc/Mdu438.32 |
0.37 |
|
| 2014 |
Lunceford JK, Cheng J, Wong P, Mehrotra DV. Ancestry Adjustments in Genome-Wide Association Studies of Randomized Clinical Trials Statistics in Biopharmaceutical Research. 6: 137-143. DOI: 10.1080/19466315.2013.873000 |
0.312 |
|
| 2004 |
Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Statistics in Medicine. 23: 2937-60. PMID 15351954 DOI: 10.1002/Sim.1903 |
0.503 |
|
| 2002 |
Lunceford JK, Davidian M, Tsiatis AA. Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials. Biometrics. 58: 48-57. PMID 11890326 DOI: 10.1111/J.0006-341X.2002.00048.X |
0.537 |
|
| Show low-probability matches. |